JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Takayasu's arteritis misdiagnosed as mediastinal malignant lymphoma: a case report and review of the literature.

Takayasu's arteritis (TA) is a rare chronic large-vessel vasculitis. The early diagnosis is difficult, because of lack of characteristic clinical manifestations. In this paper, we reported a TA case of young female was misdiagnosed as mediastinal malignant lymphoma and mediastinoscope biopsy was performed. The biopsy result demonstrated that thickened tissue adjacent to the aortic arch pathological presentations were in accord with TA. Glucocorticoid was administrated and the condition was greatly improved after treatment. Therefore, we reported this case and review of the pertinent literature in order to help clinicians improve the understanding of TA and PET/CT manifestations of TA at early phase to realize the early diagnosis and treatment of TA, finally reducing the hazards.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app